We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Danaher Corporation | NYSE:DHR | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.41 | 0.57% | 248.25 | 249.73 | 247.59 | 248.45 | 1,787,707 | 01:00:00 |
From May 2019 to May 2024
By Kimberly Chin
Danaher Corp. (DHR) has cut its full-year 2019 guidance to reflect the dilution regarding its equity offering to fund its $21.4 billion acquisition of General Electric Co.'s (GE) GE BioPharma.
For the year, Danaher now anticipates earnings of $3.34 to $3.42 a share, down from its previous forecast of $3.85 to $3.95. It expects adjusted profit of $4.72 to $4.80, a cut from its prior guidance of $4.75 to $4.85. Analysts polled by Refinitiv were expecting full-year earnings of $3.98 a share and adjusted earnings of $4.79 a share.
For the current quarter, the company projects earnings between 89 cents and 92 cents a share and adjusted earnings between $1.13 and $1.16 a share. Analysts expect earnings of 99 cents a share and adjusted earnings of $1.19 a share for the second quarter.
Shares of Danaher, which has gained 21% for the year, were mostly flat in premarket trading on low trading volumes.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 18, 2019 06:44 ET (10:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Danaher Chart |
1 Month Danaher Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
